Millipore Sigma Vibrant Logo

PC165L Anti-Opioid μ Receptor (384-398) Rabbit pAb

This Anti-Opioid µ Receptor (384-398) Rabbit pAb is validated for use in Frozen Sections, Immunoblotting, IF, IP for the detection of Opioid µ Receptor (384-398).

Anti-Opioid μ Receptor (384-398) Rabbit pAb : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.
View Products on Sigmaaldrich.com
PC165L
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

Species ReactivityHostAntibody Type
RRbPolyclonal Antibody

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
PC165L-100UL
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 100 ul
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewRecognizes the ~44-45 kDa opiod μ receptor in caudate putamen and the dorsal horn of the spinal cord.
      Catalogue NumberPC165L
      Brand Family Calbiochem®
      References
      ReferencesZaki, P.A., et al. 1996. Annu. Rev. Pharmacol. Toxicol. 36, 379.
      Arvidsson, U., et al. 1995. J. Neurosci. 15, 3328.
      Kieffer, B.L. 1995. Cell. Mol. Neurobiol. 15, 615-635.
      Childers, S.R. 1991. Life Sci. 48, 1991.
      Product Information
      FormLyophilized
      FormulationUndiluted serum.
      Positive controlRat caudate putamen or spinal cord (dorsal horn)
      PreservativeNone
      Quality LevelMQ100
      Applications
      Application ReferencesImmunoblotting Wang, X., et al. 2004. Neurosci. 129, 751. Immunoblotting, Immunofluorescence, Frozen Sections Arvidsson, U., et al. 1995. J. Neurosci. 15, 3328.
      Key Applications Frozen Sections
      Immunoblotting (Western Blotting)
      Immunofluorescence
      Immunoprecipitation
      Application NotesFrozen Sections (1:500-1:1000, Cy3 technique; 1:3000-1:6000, HRP)
      Immunoblotting (1:2000-1:2500; see application references)
      Immunofluorescence (1:100-1:200)
      Immunoprecipitation (see comments)
      Application CommentsThe specificity was determined by immunolabeling of transfected cells, immunoblotting analysis, and immunoisolation studies. Antibody specificity was examined in the rat caudate putamen and dorsal horn of the spinal cord. Staining is completely eliminated by pre-treatment of antibody with immunogen peptide at a concentration of 10 µg/ml. This antibody has also been reported to work for immunopercipitation. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogena synthetic peptide corresponding to amino acids 384-398 of rat opioid µ receptor
      ImmunogenRat
      HostRabbit
      IsotypeIgG
      Species Reactivity
      • Rat
      Antibody TypePolyclonal Antibody
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Highly Toxic
      Storage -20°C
      Do not freeze Ok to freeze
      Special InstructionsReconstitute the lyophilized antibody with 100 µl sterile distilled H₂O. Resulting reconstituted solution contains ≤0.1% sodium azide. Be careful to reconstitute the entire contents of the vial; during shipment and handling portions of the lyophilized pellet may have become dislodged and may not be in the bottom of the vial. Following reconstitution, aliquot and freeze (-20°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      PC165L-100UL 04055977209501

      Documentation

      Anti-Opioid μ Receptor (384-398) Rabbit pAb FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Anti-Opioid μ Receptor (384-398) Rabbit pAb Certificats d'analyse

      TitreNuméro de lot
      PC165L

      Références bibliographiques

      Aperçu de la référence bibliographique
      Zaki, P.A., et al. 1996. Annu. Rev. Pharmacol. Toxicol. 36, 379.
      Arvidsson, U., et al. 1995. J. Neurosci. 15, 3328.
      Kieffer, B.L. 1995. Cell. Mol. Neurobiol. 15, 615-635.
      Childers, S.R. 1991. Life Sci. 48, 1991.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision02-October-2008 RFH
      ApplicationFrozen Sections (1:500-1:1000, Cy3 technique; 1:3000-1:6000, HRP)
      Immunoblotting (1:2000-1:2500; see application references)
      Immunofluorescence (1:100-1:200)
      Immunoprecipitation (see comments)
      DescriptionRabbit polyclonal antibody supplied as lyophilized, undiluted serum. Recognizes the ~44-45 kDa opioid µ receptor protein.
      BackgroundOpioid peptides are endogenous neuromodulators, which have been identified from brain, and play a major role in the nociceptive pathway by interacting with several membrane receptors, defined as µ, δ, and κ. These peptides are derived from the cleavage of precursor proteins to produce the β-endorphin, enkephalin, and dynorphin peptides. Leu-enkephalin, Met-enkephalin, and β-endorphin all bind the µ and δ receptors with high affinity, while β-endorphin also exhibits low affinity κ binding. Dynorphin A and dynorphin B both bind the κ receptor with high affinity. In addition to these endogenous peptides, a number of exogenous nonpeptide molecules known as alkaloids or opiates also interact with the receptors to mediate a number of biological events which include the modulation of pain, analgesia, behavior, locomotor activity, and neuroendocrine physiology. Although the δ opioid receptor subtype was the first subtype identified, all three receptor classes are G protein-coupled receptors which have been shown to inhibit adenylate cyclase, decrease the conductance of voltage-gated Ca2+ channels, or activate K+ channel current.
      HostRabbit
      Immunogen speciesRat
      Immunogena synthetic peptide corresponding to amino acids 384-398 of rat opioid µ receptor
      IsotypeIgG
      Speciesrat
      Positive controlRat caudate putamen or spinal cord (dorsal horn)
      FormLyophilized
      FormulationUndiluted serum.
      PreservativeNone
      CommentsThe specificity was determined by immunolabeling of transfected cells, immunoblotting analysis, and immunoisolation studies. Antibody specificity was examined in the rat caudate putamen and dorsal horn of the spinal cord. Staining is completely eliminated by pre-treatment of antibody with immunogen peptide at a concentration of 10 µg/ml. This antibody has also been reported to work for immunopercipitation. Antibody should be titrated for optimal results in individual systems.
      Storage -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsReconstitute the lyophilized antibody with 100 µl sterile distilled H₂O. Resulting reconstituted solution contains ≤0.1% sodium azide. Be careful to reconstitute the entire contents of the vial; during shipment and handling portions of the lyophilized pellet may have become dislodged and may not be in the bottom of the vial. Following reconstitution, aliquot and freeze (-20°C).
      Toxicity Highly Toxic
      ReferencesZaki, P.A., et al. 1996. Annu. Rev. Pharmacol. Toxicol. 36, 379.
      Arvidsson, U., et al. 1995. J. Neurosci. 15, 3328.
      Kieffer, B.L. 1995. Cell. Mol. Neurobiol. 15, 615-635.
      Childers, S.R. 1991. Life Sci. 48, 1991.
      Application referencesImmunoblotting Wang, X., et al. 2004. Neurosci. 129, 751. Immunoblotting, Immunofluorescence, Frozen Sections Arvidsson, U., et al. 1995. J. Neurosci. 15, 3328.